---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001455"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2026-01-16T23:59:59+00:00"
generated_at: "2026-05-16T09:55:29.812228+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals Receives Nasdaq Non-Compliance Notice for Delayed Annual Meeting; Sets 2025 Meeting

## Summary
- Received Nasdaq letter on Jan 12, 2026 for failing to hold annual meeting within 12 months of fiscal year end.
- Company has 45 days to submit a plan to regain compliance; Nasdaq may grant exception until June 29, 2026.
- Annual meeting set for March 23, 2026 with record date of February 12, 2026.
- Stock continues trading under symbol NRXP; non-compliance indicator will be broadcast after five business days.
- Stockholder proposals or director nominations must be received by January 26, 2026.

## SEC filing metadata
- accession: 0001437749-26-001455
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2026-01-16T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000143774926001455/0001437749-26-001455-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000143774926001455/nrxp20260115_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001455
- JSON: https://secwatch.observer/filing/0001437749-26-001455.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001455.txt

## Source-grounded claims
- claim_id: 92ad23370026d7dff49a97fc0d5f5f196b41d7d5
  claim: NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5810(b)).
  evidence_excerpt: assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance within any extension period granted by Nasdaq or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules. In accordance with Nasdaq Listing Rule 5810(b), the Company is required to disclose the receipt of the Nasdaq Letter. The Nasdaq Letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, which will continue to trade under the symbol “NRXP.” However, beginning five business days from the date of the
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000143774926001455/0001437749-26-001455-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.